You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 3385 results
  1. VoiceLove: An App-Based COMmunication Tool Designed to Address DeliriUm and Improve Family ENgagement and PatIent/Family SatisfaCtion in CriticAlly Ill PaTiEnts (COMMUNICATE)

    SBC: VOICELOVE LLC            Topic: N/A

    ICU delirium is a devastating complication of illness, acute trauma, and surgery often resulting in prolonged mechanical ventilation, longer lengths of stay, and long-term disability. Delirium is associated with over 12 times increased odds of developing Alzheimer’s disease (AD) and AD-related dementias (ADRD). In addition, delirium accelerates cognitive decline in AD/ADRD patients. Likewise, pa ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Aerosolized Chemically Modified Tetracycline Nanoformulation for the Treatment of Acute Respiratory Distress Syndrome

    SBC: CMTX BIOTECH, INC.            Topic: NHLBI

    PROJECT SUMMARY/ABSTRACT CMTx Biotech is a drug development company working to rescue, develop and commercialize a proprietary clinical-stage drug candidate, incyclinide (CMT-3 / COL-3), for the treatment of sepsis patients at risk of acute respiratory distress syndrome (ARDS). According to the U.S. Centers for Disease Control (CDC), at least 1.7 million American adults develop sepsis annually, re ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL

    SBC: Actinium Pharmaceuticals, Inc.            Topic: 102

    ABSTRACT Despite treatment advances, the prognosis of adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and R/R diffuse large B-cell lymphoma (DLBCL) remains poor. Autologous T- cells modified to express a CD19-targeted chimeric antigen receptor (CAR T-cells) produce durable responses in subgroups of these patients, which has led to FDA approval of two su ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Designing and validating optimal nonaddictive analgesics using the CANDO paradigm

    SBC: MEDITATI INC            Topic: NIDA

    ABSTRACT We propose a novel holistic paradigm to help solve the opioid crisis by using proteome scale deep learning approaches to design optimal nonaddictive analgesics. We will design compounds that target specific proteins and pathways the combine the pain relieving effects of long acting drugs such as methadone and buprenorphine while modulating additional interactions to ensure optimal pharma ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Controlled-release Microbeads to Replace Growth Factors in Fetal Bovine Serum

    SBC: STEM CULTURES LLC            Topic: 400

    Scientific Abstract: The frequent use of fetal bovine serum (FBS) to support cell cultures is challenged by lot-to-lot variability, supply constraints, pathogen contaminants and ethical questions. These issues have increased significance due to the burgeoning use of FBS in cell research and therapy development. FBS has been used for over a century to culture cells, but with the need to define cult ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a novel sensor for the real-time measurement of mitral coaptation force

    SBC: MitralPint Inc.            Topic: NHLBI

    Project Summary The proposed project will develop a breakthrough endovascular sensor technology to allow for real-time quantification of the mitral coaptation force (MCF) of the mitral valve during both open and percutaneous mitral valve repair (MVR). Mitral regurgitation (MR) is the most common heart valve disorder in the U.S. population, with over 2 million individuals affected. Current methods ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. A novel platform for synthetic generation and statistical obfuscation of tabular clinical data, simulated images, and machine-generated text

    SBC: GRAYRAIN, LLC            Topic: NCATS

    PROJECT SUMMARY Data is a critical and highly valuable commodity, driving meaningful change in our society, especially when it pertains to patient care and biomedical research. Currently, institutions pay inordinate sums to increase, regain, and complement their data panels. As an extra burden, data legislation and privacy protection regulations introduce barriers to forming effective partnerships ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Structure-based computational engineering of saCas9 PAM requirement

    SBC: ATGC Inc.            Topic: 400

    ABSTRACT SaCas9 is a major gene editing nuclease that is preferred for in vivo applications thanks to its relatively smaller size compared to that of spCas9. One limiting factor for the use of saCas9 is its strict PAM requirement of NNGRRT. In addition, there are limited efforts to reduce saCas9’s off-target editing rates. In Aim 1, we propose a computational approach to relax saCas9’s PAM req ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Development of the HC2099 series of MmpL3 inhibitors to treat tuberculosis

    SBC: TARN BIOSCIENCES, INC.            Topic: NIAID

    Tarn Biosciences, Inc. is a start-up pharmaceutical company headquartered in East Lansing, Michigan. The company is developing new therapies for tuberculosis (TB). The goal of this STTR is to develop the MmpL3 inhibitor, HC2099, as a new treatment for drug susceptible and multidrug-resistant TB (MDR-TB). In 2019, 10 million people worldwide fell ill to TB with ~ 1.4 million lives lost. Standard-of ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Digital clinical hypnosis for chronic pain management

    SBC: HYPNOSCIENTIFIC, INC.            Topic: R

    Project Summary Chronic pain is a prevalent, disabling problem affecting as many as 116 million adults in the United States. However, there are very few treatment options for chronic pain management, and those that are available are inadequate for the majority of those with this condition. Many also have significant negative side effects or are associated with significant adverse events. A growing ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government